- Home
- RLMD vs APRE Comparison
RLMD vs APRE Comparison
Compare RLMD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- APRE
- Stock Information
- Founded
- RLMD 2004
- APRE 2006
- Country
- RLMD United States
- APRE United States
- Employees
- RLMD N/A
- APRE N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLMD Health Care
- APRE Health Care
- Exchange
- RLMD Nasdaq
- APRE Nasdaq
- Market Cap
- RLMD 11.5M
- APRE 13.5M
- IPO Year
- RLMD N/A
- APRE 2019
- Fundamental
- Price
- RLMD $0.30
- APRE $1.87
- Analyst Decision
- RLMD Hold
- APRE Strong Buy
- Analyst Count
- RLMD 4
- APRE 2
- Target Price
- RLMD $4.25
- APRE $15.50
- AVG Volume (30 Days)
- RLMD 382.7K
- APRE 21.0K
- Earning Date
- RLMD 03-27-2025
- APRE 05-13-2025
- Dividend Yield
- RLMD N/A
- APRE N/A
- EPS Growth
- RLMD N/A
- APRE N/A
- EPS
- RLMD N/A
- APRE N/A
- Revenue
- RLMD N/A
- APRE $1,502,581.00
- Revenue This Year
- RLMD N/A
- APRE N/A
- Revenue Next Year
- RLMD N/A
- APRE N/A
- P/E Ratio
- RLMD N/A
- APRE N/A
- Revenue Growth
- RLMD N/A
- APRE 157.63
- 52 Week Low
- RLMD $0.24
- APRE $1.85
- 52 Week High
- RLMD $5.09
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- RLMD 50.05
- APRE 26.70
- Support Level
- RLMD $0.26
- APRE $2.17
- Resistance Level
- RLMD $0.32
- APRE $2.30
- Average True Range (ATR)
- RLMD 0.02
- APRE 0.17
- MACD
- RLMD 0.00
- APRE -0.01
- Stochastic Oscillator
- RLMD 67.34
- APRE 2.50
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.